Efficacy of Pharmacist Interventions Through the "Medication Therapy Management Pathway in Hypertensive Patients"

Hypertension Clinical Trial

— PharmMTMH  

Official title:

Efficacy of Pharmacist Interventions Through the "Medication Therapy Management Pathway in Hypertensive Patients":A Prospective, Multicenter, Randomized, Controlled Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06310512
• Other study ID #: ANZHEN HOSPITOL-LY-04
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 1, 2024
• Est. completion date: June 30, 2026

Study information

• Verified date: March 2024
• Source: Beijing Anzhen Hospital
• Contact: JuanJuan Wei, MS
• Phone: 01064456609
• Email: weijj2005[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this Randomized Controlled Trial is to carry out in adult patients with primary hypertension whose blood pressure control is not up to standard. The main question it aims to answer are: To explore the effect of pharmacists' implementation of "the medication therapy management pathway in hypertensive patients"on the patients with hypertension. Participants will receive structured drug treatment management at the first diagnosis. During on-site follow-up in the first, third and sixth months, as well as telephone follow-up in the second week, second and fourth months, patients will be evaluated, corresponding information will be collected and possible interventions will be taken. Researchers will compare the non intervention group to see if patients' blood pressure will also be reduced without intervention.

Description:

The purpose of this study is to explore the effectiveness, safety, and cost-effectiveness of pharmacists implementing the Drug Treatment Management Pathway in the treatment of hypertension patients. This trial is a prospective, multi-center, randomized, controlled study. We plan to enroll 420 patients with primary hypertension who are over 18 years old and whose blood pressure control is not up to standard. Qualified participants who meet the inclusion and exclusion criteria were randomly divided into an intervention group of 280 cases and a non intervention group of 140 cases in a 2:1 ratio.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 420
• Est. completion date: June 30, 2026
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age =18 years old, male or female;

2. Outpatients diagnosed with primary hypertension who have not received treatment or are receiving antihypertensive medication;

3. Mild to moderate hypertensive patients with substandard blood pressure: home blood pressure >140/90 mmHg at least once in the last month or more, and the average sitting blood pressure in the clinic on the day of enrollment is >140/90 mmHg;

4. Expected survival > 12 months;

5. Voluntary participation in the trial and signing the informed consent form.

Exclusion Criteria:

1. Severe hypertension (mean SBP =180mmHg, or mean DBP =110mmHg), hypertensive emergency or hypertensive sub-emergency (systolic blood pressure >180 mmHg or diastolic blood pressure >120 mmHg);

2. Have a history or diagnosis of secondary hypertension, including but not limited to the following: renal hypertension, renal vascular hypertension, aortic stenosis, pheochromocytoma, Cushing's syndrome, cystic nephropathy, etc., but drug-induced hypertension is not an exclusion criterion;

3. Patients in the acute stage of the disease requiring emergency medical consultation;

4. patients with mental disorder, hearing impairment, intellectual disability, aphasia, etc., resulting in the inability to communicate or to comply with the study agreement

5. Patients with tumors;

6. Any other reasons that the investigator considers unsuitable for participation in the clinical trial that may affect the efficacy and safety evaluation of the study (including, but not limited to, the investigator's judgment that the subject lives far away and cannot be followed up as scheduled).

Related Conditions & MeSH terms

• Hypertension
• Medication Therapy Management

Intervention

Behavioral:
• Structured drug therapy management
Interventions mainly included (1) information collection, clinical assessment, and evaluation of medication regimens; (2) identification of and intervention for medication-related problems; (3) pharmacy instruction and education, and development of personal medication lists; and (4) follow-up and reassessment

Locations

Country	Name	City	State
China	Beijing Anzhen Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Anzhen Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	systolic blood pressure	Change from baseline in mean seated systolic blood pressure at 6 months	6 months
Secondary	diastolic blood pressure	Changes from baseline in mean seated diastolic blood pressure at 6 months	6 months
Secondary	Change from baseline in mean sitting systolic blood pressure at 3 months	Change from baseline in mean sitting systolic blood pressure at 3 months	3 months
Secondary	Change from baseline in number of medication-related problems (MRP) at 6 months	Change from baseline in number of medication-related problems (MRP) at 6 months	6 months
Secondary	Average number of medication-related problems (MRP) resolved after 6 months	Average number of medication-related problems (MRP) resolved after 6 months	6 months
Secondary	The compliance rate of blood pressure after 6 months	The compliance rate of blood pressure after 6 months	6 months
Secondary	Effective rate of blood pressure lowering after 6 months	Effective rate of blood pressure lowering after 6 months	6 months
Secondary	Time to BP Attainment in Intervention and Non-Intervention Groups	Time to BP Attainment in Intervention and Non-Intervention Groups	From the date of enrollment to the date when the patient's first blood pressure meets the standard, the evaluation is conducted up to 6 months
Secondary	Changes from baseline in adherence scores at 6 months,the General Medication Compliance Scale (GMAS) was used.	The General Medication Compliance Scale (GMAS) was used, with a maximum score of 33 and a minimum score of 0. The higher the score, the higher the patient's compliance.	6 months
Secondary	Economic indicators,mainly including the cost of implementing intervention measures and the impact of intervention measures on patient diagnosis and treatment costs	The implementation costs of intervention measures mainly include the development, installation, and annual maintenance costs of Interactive Network Response System (IWRS), labor costs of intervention measures, material costs incurred during the intervention process, multi center collaboration costs, and other costs incurred due to the intervention measures. Intervention measures have an impact on patient diagnosis and treatment costs, mainly including an increase in per visit outpatient expenses and medication costs.	6 months